1 Reason This $900 Stock Could Announce a Split in 2026

Shares of Eli Lilly (NYSE: LLY) are hovering conscionable beneath the $900 level, placing the institution among high-priced stocks wherever banal divided speculation often builds.

While a divided does not alteration the fundamentals of the underlying business, it makes the banal much liquid and increases its entreaty to a wider capitalist base. Stock splits often bespeak management's assurance successful the company's sustained semipermanent growth. That's precisely what makes Eli Lilly basal retired today.

Will AI make the world's archetypal trillionaire? Our squad conscionable released a study connected the 1 little-known company, called an "Indispensable Monopoly" providing the captious exertion Nvidia and Intel some need. Continue »

Eli Lilly has emerged arsenic a ascendant unit successful obesity and metabolic health. Its incretin-based (GLP-1) drugs, Mounjaro and Zepbound, are seeing a coagulated emergence successful diligent volumes, with maturation progressively driven by request alternatively than pricing. Mounjaro's gross surged 99% twelvemonth implicit twelvemonth to astir $23 billion, portion Zepbound's gross soared 175% twelvemonth implicit twelvemonth to astir $13.5 cardinal successful 2025.

Despite beardown adoption, GLP-1 cause penetration remains successful the mid-single digits among the eligible obesity colonisation successful the U.S. This suggests important country for Eli Lilly's obesity portfolio to turn successful the future. The obesity marketplace whitethorn grow adjacent further, arsenic the institution prepares to motorboat oral GLP-1 therapy orforglipron, which could bring successful patients who person truthful acold avoided injectable treatments.

In fiscal 2025, Eli Lilly's full gross surged 45% twelvemonth implicit twelvemonth to astir $65.2 billion, portion net per stock roseate 86% twelvemonth implicit twelvemonth to $24.2. The institution is guiding for fiscal 2026 gross successful the scope of $80 cardinal to $83 billion. While absorption expects pricing of its cardinal products to resistance gross maturation by low- to mid-teens percentage, measurement maturation is acceptable to much than offset it. This highlights that the request for Eli Lilly's drugs is some broad-based and durable.

Eli Lilly has committed implicit $55 cardinal toward manufacturing enlargement since 2020. The institution is besides advancing 36 progressive late-stage signifier 3 programs. Considering the stock's terms appreciation and the company's awesome gross tailwinds, Eli Lilly seems well-positioned for a imaginable banal divided successful 2026.

Before you bargain banal successful Eli Lilly, see this:

The Motley Fool Stock Advisor expert squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Eli Lilly wasn’t 1 of them. The 10 stocks that made the chopped could nutrient monster returns successful the coming years.